CYCC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYCC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cyclacel Pharmaceuticals's total current liabilities for the quarter that ended in Dec. 2023 was $8.16
The historical data trend for Cyclacel Pharmaceuticals's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclacel Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Current Liabilities | Get a 7-Day Free Trial | 2.42 | 2.49 | 5.41 | 7.51 | 8.16 |
Cyclacel Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Current Liabilities | Get a 7-Day Free Trial | 7.51 | 7.34 | 6.75 | 8.15 | 8.16 |
Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.
Cyclacel Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 7.781 | + | 0 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 0.38 | + | 0 | |
= | 8.16 |
Cyclacel Pharmaceuticals's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 7.781 | + | 0 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 0.38 | + | 0 | |
= | 8.16 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Be Aware
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Spiro Rombotis | director, officer: President & C.E.O. | C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922 |
Paul Mcbarron | director, officer: E.V.P., Finance & C.O.O. | C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922 |
Kenneth M. Ferguson | director | 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121 |
Sam L Barker | director | 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525 |
Brian Schwartz | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Karin L Walker | director | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Mark Kirschbaum | officer: Chief Medical Officer | 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Eastern Capital Ltd | 10 percent owner | 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Kevin C Tang | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Partners Lp | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Management Llc | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Portfolio Services Ltd. | 10 percent owner | 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Kenneth Bryan Dart | 10 percent owner | P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206 |
Lloyd Sems | director | C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017 |
From GuruFocus
By PRNewswire PRNewswire • 08-11-2022
By PurpleRose PurpleRose • 07-10-2022
By GlobeNewswire • 11-28-2023
By sperokesalga sperokesalga • 05-04-2023
By GuruFocusNews GuruFocusNews • 07-10-2022
By GuruFocusNews GuruFocusNews • 06-30-2022
By PurpleRose PurpleRose • 08-03-2022
By Value_Insider Value_Insider • 11-09-2022
By GuruFocusNews GuruFocusNews • 06-22-2022
By PurpleRose PurpleRose • 07-12-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.